These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7902245)

  • 1. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
    Criscuoli M; Lippi A; Mengozzi G; Sardelli G; Subissi A; Giachetti A
    Drug Metab Dispos; 1993; 21(5):835-40. PubMed ID: 7902245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of idrapril calcium on tissue angiotensin-converting enzyme in rats.
    Becagli P; Lippi A; Criscuoli M; Breschi MC; Subissi A
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):27-32. PubMed ID: 7564361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
    Zanchi A; Nussberger J; Criscuoli M; Capone P; Brunner HR
    J Cardiovasc Pharmacol; 1994 Aug; 24(2):317-22. PubMed ID: 7526067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral pharmacokinetics and pharmacodynamics of idrapril calcium, the prototype of a new class of angiotensin converting enzyme inhibitors, in humans.
    Criscuoli M; Subissi A; Coppini A; Capone P; Taddei S; Salvetti A
    J Hypertens Suppl; 1993 Dec; 11(5):S340-1. PubMed ID: 8158413
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
    Wyld PJ; Grant J; Lippi A; Criscuoli M; Del Re G; Subissi A
    Br J Clin Pharmacol; 1994 Nov; 38(5):421-5. PubMed ID: 7893583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors.
    Subissi A; Criscuoli M; Sardelli G; Guelfi M; Giachetti A
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):139-46. PubMed ID: 1383623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogs.
    Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
    Arzneimittelforschung; 1992 Apr; 42(4):457-65. PubMed ID: 1642668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
    Grubb MF; Wong YN; Burcham DL; Saxton PL; Quon CY; Huang SM
    Drug Metab Dispos; 1994; 22(5):709-12. PubMed ID: 7835221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
    Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
    Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.
    Taddei S; Ghiadoni L; Mattei P; Sudano I; Duranti P; Favilla S; Virdis A; Romagnoli A; Criscuoli M; Coppini A
    Eur J Clin Pharmacol; 1995; 48(5):339-43. PubMed ID: 8641320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
    Hirayama M; Kurihara A; Manabe T; Hasegawa Y
    Drug Metab Dispos; 1994; 22(4):601-6. PubMed ID: 7956736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
    Monbaliu J; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2003; 53(7):486-95. PubMed ID: 12918214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN; Mauron C; Kaiser G
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.